Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

• Published in: Endocrine Journal Vol. 71; no. 3; pp. 233 - 244
• Main Authors: Lu, Xiuyan, Chen, Yinghui, Cui, Na, Feng, Yonghao, Shi, Xiaohong, Wang, Ming, Huang, Yongmei
• Format: Journal Article
• Language: English
• Published: Japan The Japan Endocrine Society 01.01.2024; Japan Science and Technology Agency
• Subjects: Alirocumab; Diabetes mellitus; Diabetic neuropathy; Diabetic peripheral neuropathy; Dyslipidemia; High fat diet; Inflammation; Inflammatory response; Kexin; Nerve conduction; Oxidative stress; Peripheral neuropathy; Proprotein convertases; Risk factors; Sciatic nerve; Streptozocin; Subtilisin; Oxidative stress; Inflammatory response; Alirocumab; Diabetic peripheral neuropathy; Sciatic nerve

Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use. The role of PCSK9 in diabetic peripheral neuropathy is still unclear. In this...